On July 10, 2024, the Minhang District Agriculture and Rural Affairs Committee of Shanghai Municipality, together with a group of experts from the Minhang District Animal Pathogen Microorganism Laboratory Biosafety Management Expert Pool, conducted an on-site inspection of the Biosafety Level 2 (BSL-2) laboratory of Shenlian Biomedical . The inspection team listened to the laboratory's work report and conducted an on-site inspection of the laboratory layout and operation records. Through the inspection, the inspection team unanimously agreed that the Shenlian Biomedical BSL-2 laboratory has been well-managed and operated, and its biosafety measures have been effectively implemented, meeting the basic requirements of a BSL-2 laboratory and providing a guarantee for conducting relevant animal pathogen microorganism experiments.

After comprehensive evaluation by the expert panel, the Shenlian Biomedical BSL-2 laboratory passed the on-site inspection and obtained the Biosafety Level 2 (BSL-2) Laboratory Registration Certificate on August 13, 2024.

The Biosafety Level 2 (BSL-2) laboratory of Shenlian Biomedical is a crucial research platform for driving the company's research innovation and technological breakthroughs. The successful registration signifies that the laboratory can now conduct the isolation, identification, and detection of animal pathogens within the scope of its registration, which will significantly enhance the laboratory's research capabilities and accelerate the development of the company's biological products for economic animals and pets. Moreover, it will rapidly promote the company's work in standard substance preparation, clinical diagnosis, and product efficacy evaluation, providing customers with more, better, and more professional technical services.

Going forward, Shenlian Biomedical will strictly adhere to the national and local laws and regulations on the biosafety of pathogen laboratories, building a safe and efficient BSL-2 laboratory. The company will focus on the scientific research of animal pathogens and is committed to developing more novel veterinary biological products to better serve the market, meet customer needs, and contribute to the development of the animal health industry.